| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Natural vitamin E analog; Garcinoic acid (trans-13'-carboxyl-8-tocotrienol) was evaluated for antiproliferative activity against glioma C6 cancer cells. [1]
|
|---|---|
| ln Vitro |
Garcinoic acid (1) was tested for antiproliferative effect on murine glioma C6 cancer cells. At a final concentration of 10 μM for 24 hours, garcinoic acid showed a marked inhibition of cell growth, though less pronounced than its saturated analogue (13'-carboxy-δ-tocopherol, compound 5) and the corresponding alcohol (13'-hydroxy-α-tocopherol, compound 7). [1]
|
| Cell Assay |
Cell Assay:
Cell Proliferation Assay (Glioma C6 cells): Murine glioma C6 cells were cultured and incubated with compounds including garcinoic acid (1) at a final concentration of 10 μM for 24 hours. Cell viability was measured by flow cytometry using FITC-annexin V and propidium iodide (PI) staining. FITC-annexin V and PI were added to a final concentration of 1 μg/mL. Cells were incubated for 20 minutes in the dark at 37°C and then processed for flow cytometric analysis. For each experimental condition, 20,000 events were counted. Cell viability was measured as the percentage of annexin V- and PI-negative cells. Proliferation was expressed as the cells number ratio between the samples exposed to compounds and the untreated control sample. [1]
|
| References | |
| Additional Infomation |
Reports indicate that (2E,6E,10E)-13-[(2S)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromene-2-yl]-2,6,10-trimethyl-tetadecan-2,6,10-trienoic acid has been discovered in Garcinia kola, and relevant data are available.
Garcinoic acid (trans-13'-carboxyl-8-tocotrienol) is a vitamin E analogue extracted from the seeds of Garcinia kola. It was first isolated from the fruits of Clusia grandiflora and is also found in other plants. The compound has previously shown antioxidant, antibacterial, and DNA polymerase β inhibitor activities. [1] Based on optical rotation measurements, garcinoic acid extracted from Garcinia kola seeds was previously reported as a racemate. However, through chemical transformation to α-tocopherol followed by chiral HPLC analysis on a Chiralcel OD-H column, the sample was determined to be enantiopure with R configuration at carbon 2 of the chroman ring. The CD spectrum of garcinoic acid in methanol showed a positive peak at 208 nm (+9.6), indicating it is not a racemate. [1] In a preliminary antiproliferative test on glioma C6 cells, garcinoic acid and its derivatives (compounds 3-5, 7) showed marked inhibition of cell growth. The presence of a carboxylic or alcoholic group in the vitamin E derivatives enhanced the antiproliferative effect, while the length of the side chain seemed to have little influence on this cell line. [1] |
| Molecular Formula |
C27H38O4
|
|---|---|
| Exact Mass |
426.277
|
| Elemental Analysis |
C, 76.02; H, 8.98; O, 15.00
|
| CAS # |
91893-83-3
|
| PubChem CID |
133556427
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
602.6±55.0 °C at 760 mmHg
|
| Flash Point |
195.8±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
8.34
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
31
|
| Complexity |
689
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1C=C(O)C=C2CC[C@@](OC=12)(C)CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/C(=O)O
|
| InChi Key |
QOFWRHWADNWKSU-XRBHEKJPSA-N
|
| InChi Code |
InChI=1S/C27H38O4/c1-19(11-7-13-21(3)26(29)30)9-6-10-20(2)12-8-15-27(5)16-14-23-18-24(28)17-22(4)25(23)31-27/h9,12-13,17-18,28H,6-8,10-11,14-16H2,1-5H3,(H,29,30)/b19-9+,20-12+,21-13+/t27-/m0/s1
|
| Chemical Name |
(2E,6E,10E)-13-[(2S)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid
|
| Synonyms |
Garcinoic acid; (2E,6E,10E)-13-[(2R)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid; DTXSID101334845; (2E,6E,10E)-13-((2R)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienoic acid; 91893-83-3;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
